The relationship between TP53 Gene Mutation with treatment results in High-Grade Gliomas
Keywords:
genes TP53, mutation, gliomas, treatment outcome.Abstract
Introduction: Determining the relationship between TP53 gene mutation and treatment outcome in high-grade gliomas patients has great significance for disease prognosis and treatment outcome monitoring.
Ojectives: To determine the relationship between TP53 gene mutation rate and some characteristics of treatment outcome in high-grade gliomas patients.
Methods: The study was conducted by descriptive method, on 52 high-grade gliomas patients at Vietnam National Cancer Hospital, from January 2019 to December 2020. Based on statistics of clinical symptoms, paraclinical tests and post-operative monitoring results, it was evaluated the relationship between TP53 gene mutation in study patients with response to treatment and patient's survival time.
Results: There was a relationship between TP53 gene mutation and response to treatment according to Response Evaluation Criteria In Solid Tumors (p= 0.004). Progression-free survival was higher in the group with the TP53 mutation than in the group without the TP53 mutation (χ2= 6.7; p= 0.010). The overall survival in the group with the TP53 mutation was higher than the overall survival in the group without the TP53 mutation (χ2= 2.6; p= 0.107).
Conclusion: There is a relationship between the occurrence of TP53 gene mutations with treatment response criteria and progression-free survival in patients with high-grade gliomas.
Downloads
Download data is not yet available.
References
1. Walker EV, Davis FG. Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013 [Internet]. Neuro-oncology. 2019; 21(3):360-9. DOI: 10.1093/neuonc/noy195
2. Jung YL, Yoo HS, Kim ES. The relationship between government research funding and the cancer burden in South Korea: implications for prioritising health research [Internet]. Health Research Policy and Systems. 2019; 17(1):1-12. DOI: 10.1186/s12961-019-0510-6
3. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M. Changing Paradigms - An Update on the Multidisciplinary Management of Malignant Glioma [Internet]. The Oncologist. 2006; 11(2):165-80. DOI: 10.1634/theoncologist.11-2-165
4. Habib A, Pease M, Kodavali CV, Amankulor N, Zinn PO. A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care [Internet]. J Neurooncol. 2021; 151:103-12. DOI: 10.1007/s11060-020-03671-w
5. Kristensen BW, Priesterbach-Ackley LP, Petersen JK, Wesseling P. Molecular pathology of tumors of the central nervous system [Internet]. Annals of oncology. 2019; 30(8):1265-78. DOI: 10.1093/annonc/mdz164
6. Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma [Internet]. Nature immunology. 2019; 20(9):1100-09. DOI: 10.1038/s41590-019-0433-y
7. Nasrallah MP, Binder ZA, Oldridge DA, Zhao J, Lieberman DB, Roth JJ, et al. Molecular neuropathology in practice: clinical profiling and integrative analysis of molecular alterations in glioblastoma [Internet]. Academic pathology. 2019; 6: 2374289519848353. DOI: 10.1177/2374289519848353
8. Buccoliero AM, Giunti L, Moscardi S, Castiglione F, Provenzano A, Sardi I, et al. Pediatric high grade glioma classification criteria and molecular features of a case series [Internet]. Genes. 2022; 13(4):624. DOI: 10.3390/genes13040624
9. Reuss DE, Downing SM, Camacho CV, Wang YD, Piro RM, Herold-Mende C, et al. Simultaneous Nbs1 and p53 inactivation in neural progenitors triggers High-Grade Gliomas [Internet]. Neuropathology and Applied Neurobiology. 2023; 49(4):e12915. DOI: 10.1111/nan.12915
10. Liao F, Yuan L, Zhu J, Chen W, Zhao Y, He J. Association of TP53 rs1042522 C>G polymorphism with glioma risk in Chinese children [Internet]. BioMed Research International. 2022; 2022:1-6. DOI: 10.1155/2022/2712808
11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group [Internet]. American journal of clinical oncology. 1982 [access: 05/12/2023]; 5(6):649-55. Available from: https://journals.lww.com/amjclinicaloncology/Abstract/1982/12000/Toxicity_and_-response_criteria_of_the_Eastern.14.aspx
12. Kuhl CK, Alparslan Y, Schmoee J, Sequeira B, Keulers A, Brümmendorf TH, et al. Validity of RECIST version 1.1 for response assessment in metastatic cancer: a prospective, multireader study [Internet]. Radiology. 2019; 290(2): 349-56. DOI: 10.1148/radiol.2018180648
13. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations [Internet]. Journal of the American Statistical Association. 1958; 53(282):457-81. DOI: 10.1080/01621459.1958.10501452
14. Tada M, Iggo RD, Waridel F, Nozaki M, Matsumoto R, Abe H. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses [Internet]. Mol Carcinog. 1997; 18(3):171-6. DOI: 10.1002/(SICI)1098-2744(199703)18:3<171::AID-MC6>3.0.CO;2-I
15. Hayes VM, Dirven CM, Dam A, Verlind E, Molenaar WM, Mooij JJ, et al. High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors [Internet]. Brain Pathology. 1999; 9(3):463-7. DOI: 10.1111/j.1750-3639.1999.tb00535.x
16. Mathur R, Zhang Y, Grimmer MR, Hong C, Zhang M, Bollam S, et al. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence [Internet]. Neuro-oncology. 2020; 22(11): 1580-90. DOI: 10.1093/neuonc/noaa059
17. Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma [Internet]. Nature Reviews Neurology. 2019; 15(7):405-17. DOI: 10.1038/s41582-019-0220-2
18. Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, et al. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma [Internet]. Clinical Cancer Research, clincanres. 2014; 20(19):5023-31. DOI: 10.1158/1078-0432.CCR-14-0822
19. Golebiewska A, Hau AC, Oudin A, Stieber D, Yabo YA, Baus V, et al. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology [Internet]. Acta Neuropathologica. 2020; 140(2):919-49. DOI: 10.1007/s00401-020-02226-7
20. Blough MD, Beauchamp DC, Westgate MR, Kelly JJ, Cairncross JG. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma [Internet]. Journal of Neuro-oncology. 2011; 102(1):1-7. DOI: 10.1007/s11060-010-0283-9
21. Nakahara Y, Ito H, Namikawa H, Furukawa T, Yoshioka F, Ogata A, et al. A tumor suppressor gene, N-myc downstream-regulated gene 1 (NDRG1), in gliomas and glioblastomas [Internet]. Brain Sciences. 2022; 12(4): 473. DOI: 10.3390/brainsci12040473
22. Laviv Y, Berkowitz S, Kanner AK, Fichman S, Benouaich-Amiel A, Siegal T, et al. Gemistocytes in newly diagnosed glioblastoma multiforme: Clinical significance and practical implications in the modern era [Internet]. Journal of Clinical Neuroscience. 2021; 88:120-7. DOI: 10.1016/j.jocn.2021.03.034
23. Hausser J, Alon U. Tumour heterogeneity and the evolutionary trade-offs of cancer [Internet]. Nature Reviews Cancer. 2020; 20(4):247-57. DOI: 10.1038/s41568-020-0241-6
24. Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, et al. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations [Internet]. Cancer Research. 1998 [access: 05/12/2023]; 58(9):1793-7. Available from: https://aacrjournals.org/cancerres/article/58/9/1793/505056/Selective-Sensitivity-to-Radiation-of-Cerebral
25. Woo PY, Li Y, Chan AH, Ng SC, Loong HH, Chan DT, et al. A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase [Internet]. Glioma. 2019; 2(2):68-82. DOI: 10.4103/glioma.glioma_3_19
26. Kaina B, Christmann M. DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas [Internet]. DNA repair. 2019; 78:128-41. DOI: 10.1016/j.dnarep.2019.04.007
27. Kinashi Y, Ikawa T, Takahashi S. The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status [Internet]. Applied Radiation and Isotopes. 2020; 163:109204. DOI: 10.1016/j.apradiso.2020.109204
2. Jung YL, Yoo HS, Kim ES. The relationship between government research funding and the cancer burden in South Korea: implications for prioritising health research [Internet]. Health Research Policy and Systems. 2019; 17(1):1-12. DOI: 10.1186/s12961-019-0510-6
3. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M. Changing Paradigms - An Update on the Multidisciplinary Management of Malignant Glioma [Internet]. The Oncologist. 2006; 11(2):165-80. DOI: 10.1634/theoncologist.11-2-165
4. Habib A, Pease M, Kodavali CV, Amankulor N, Zinn PO. A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care [Internet]. J Neurooncol. 2021; 151:103-12. DOI: 10.1007/s11060-020-03671-w
5. Kristensen BW, Priesterbach-Ackley LP, Petersen JK, Wesseling P. Molecular pathology of tumors of the central nervous system [Internet]. Annals of oncology. 2019; 30(8):1265-78. DOI: 10.1093/annonc/mdz164
6. Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma [Internet]. Nature immunology. 2019; 20(9):1100-09. DOI: 10.1038/s41590-019-0433-y
7. Nasrallah MP, Binder ZA, Oldridge DA, Zhao J, Lieberman DB, Roth JJ, et al. Molecular neuropathology in practice: clinical profiling and integrative analysis of molecular alterations in glioblastoma [Internet]. Academic pathology. 2019; 6: 2374289519848353. DOI: 10.1177/2374289519848353
8. Buccoliero AM, Giunti L, Moscardi S, Castiglione F, Provenzano A, Sardi I, et al. Pediatric high grade glioma classification criteria and molecular features of a case series [Internet]. Genes. 2022; 13(4):624. DOI: 10.3390/genes13040624
9. Reuss DE, Downing SM, Camacho CV, Wang YD, Piro RM, Herold-Mende C, et al. Simultaneous Nbs1 and p53 inactivation in neural progenitors triggers High-Grade Gliomas [Internet]. Neuropathology and Applied Neurobiology. 2023; 49(4):e12915. DOI: 10.1111/nan.12915
10. Liao F, Yuan L, Zhu J, Chen W, Zhao Y, He J. Association of TP53 rs1042522 C>G polymorphism with glioma risk in Chinese children [Internet]. BioMed Research International. 2022; 2022:1-6. DOI: 10.1155/2022/2712808
11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group [Internet]. American journal of clinical oncology. 1982 [access: 05/12/2023]; 5(6):649-55. Available from: https://journals.lww.com/amjclinicaloncology/Abstract/1982/12000/Toxicity_and_-response_criteria_of_the_Eastern.14.aspx
12. Kuhl CK, Alparslan Y, Schmoee J, Sequeira B, Keulers A, Brümmendorf TH, et al. Validity of RECIST version 1.1 for response assessment in metastatic cancer: a prospective, multireader study [Internet]. Radiology. 2019; 290(2): 349-56. DOI: 10.1148/radiol.2018180648
13. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations [Internet]. Journal of the American Statistical Association. 1958; 53(282):457-81. DOI: 10.1080/01621459.1958.10501452
14. Tada M, Iggo RD, Waridel F, Nozaki M, Matsumoto R, Abe H. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses [Internet]. Mol Carcinog. 1997; 18(3):171-6. DOI: 10.1002/(SICI)1098-2744(199703)18:3<171::AID-MC6>3.0.CO;2-I
15. Hayes VM, Dirven CM, Dam A, Verlind E, Molenaar WM, Mooij JJ, et al. High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors [Internet]. Brain Pathology. 1999; 9(3):463-7. DOI: 10.1111/j.1750-3639.1999.tb00535.x
16. Mathur R, Zhang Y, Grimmer MR, Hong C, Zhang M, Bollam S, et al. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence [Internet]. Neuro-oncology. 2020; 22(11): 1580-90. DOI: 10.1093/neuonc/noaa059
17. Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma [Internet]. Nature Reviews Neurology. 2019; 15(7):405-17. DOI: 10.1038/s41582-019-0220-2
18. Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, et al. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma [Internet]. Clinical Cancer Research, clincanres. 2014; 20(19):5023-31. DOI: 10.1158/1078-0432.CCR-14-0822
19. Golebiewska A, Hau AC, Oudin A, Stieber D, Yabo YA, Baus V, et al. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology [Internet]. Acta Neuropathologica. 2020; 140(2):919-49. DOI: 10.1007/s00401-020-02226-7
20. Blough MD, Beauchamp DC, Westgate MR, Kelly JJ, Cairncross JG. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma [Internet]. Journal of Neuro-oncology. 2011; 102(1):1-7. DOI: 10.1007/s11060-010-0283-9
21. Nakahara Y, Ito H, Namikawa H, Furukawa T, Yoshioka F, Ogata A, et al. A tumor suppressor gene, N-myc downstream-regulated gene 1 (NDRG1), in gliomas and glioblastomas [Internet]. Brain Sciences. 2022; 12(4): 473. DOI: 10.3390/brainsci12040473
22. Laviv Y, Berkowitz S, Kanner AK, Fichman S, Benouaich-Amiel A, Siegal T, et al. Gemistocytes in newly diagnosed glioblastoma multiforme: Clinical significance and practical implications in the modern era [Internet]. Journal of Clinical Neuroscience. 2021; 88:120-7. DOI: 10.1016/j.jocn.2021.03.034
23. Hausser J, Alon U. Tumour heterogeneity and the evolutionary trade-offs of cancer [Internet]. Nature Reviews Cancer. 2020; 20(4):247-57. DOI: 10.1038/s41568-020-0241-6
24. Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, et al. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations [Internet]. Cancer Research. 1998 [access: 05/12/2023]; 58(9):1793-7. Available from: https://aacrjournals.org/cancerres/article/58/9/1793/505056/Selective-Sensitivity-to-Radiation-of-Cerebral
25. Woo PY, Li Y, Chan AH, Ng SC, Loong HH, Chan DT, et al. A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase [Internet]. Glioma. 2019; 2(2):68-82. DOI: 10.4103/glioma.glioma_3_19
26. Kaina B, Christmann M. DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas [Internet]. DNA repair. 2019; 78:128-41. DOI: 10.1016/j.dnarep.2019.04.007
27. Kinashi Y, Ikawa T, Takahashi S. The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status [Internet]. Applied Radiation and Isotopes. 2020; 163:109204. DOI: 10.1016/j.apradiso.2020.109204
Published
2024-05-16
How to Cite
1.
Nguyen BT, Tran DA, Ngo HQ, Nguyen TH, Ngo HK. The relationship between TP53 Gene Mutation with treatment results in High-Grade Gliomas. Rev Cubana Med Milit [Internet]. 2024 May 16 [cited 2025 Jun. 12];53(2):e024035778. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/35778
Issue
Section
Research Article
License
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.
